Surface Oncology Inc (NASDAQ:SURF)

1.72
Delayed Data
As of 3:59pm ET
 -0.05 / -2.82%
Today’s Change
1.37
Today|||52-Week Range
8.38
-64.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$112.3M

Company Description

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm's pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Contact Information

Surface Oncology, Inc.
50 Hampshire Street
Cambridge Massachusetts 02139
P:(617) 714-4096
Investor Relations:

Employees

Shareholders

Other institutional30.93%
Individual stakeholders30.59%
Mutual fund holders22.06%

Top Executives

Robert W. RossPresident, Chief Executive Officer & Director
Jessica FeesChief Financial Officer
Vito J. PalombellaChief Scientific Officer
Alison M. O'NeillChief Medical Officer
Lauren HarshmanVP-Clinical Development